Shots:

• The life science portfolio to be acquired includes label-free biomolecular characterization (FortéBio)- chromatography hardware and resins- and microcarriers (SoloHill) businesses. The proposed transaction follows Danaher’s GE Biopharma business and related regulatory approval
• The transaction is expected to be completed in Q1’20 and will strengthen Sartorius’ presence in bioanalytics and bioprocessing segments with the acquisition of Danaher’s life science platform businesses
• Danaher’s FortéBio comprises protein analysis instruments- biosensors and reagents- used in drug discovery while its SoloHill includes microcarrier technology and particle validation standards used in cell culture and other bioprocesses

Click here to­ read full press release/ article | Ref: Businesswire | Image: MPO-mag